Human Albumin Fragments Nanoparticles as PTX Carrier for Improved Anti-cancer Efficacy | Zendy

Liang Ge | Zendy; Xinru You | Zendy; Jun Huang | Zendy; Yuejian Chen | Zendy; Li Chen | Zendy; Ying Zhu | Zendy; Yuan Zhang | Zendy; Xiqiang Liu | Zendy; Jun Wu | Zendy; Hai Qian | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Human Albumin Fragments Nanoparticles as PTX Carrier for Improved Anti-cancer Efficacy

Author(s) -

Liang Ge,

Xinru You,

Jun Huang,

Yuejian Chen,

Li Chen,

Ying Zhu,

Yuan Zhang,

Xiqiang Liu,

Jun Wu,

Hai Qian

Publication year - 2018

Publication title -

frontiers in pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.384

H-Index - 86

ISSN - 1663-9812

DOI - 10.3389/fphar.2018.00582

Subject(s) - human serum albumin , paclitaxel , biocompatibility , albumin , drug , drug delivery , chemistry , internalization , pharmacology , drug carrier , serum albumin , cancer , nanoparticle , genipin , bovine serum albumin , nanotechnology , medicine , materials science , biochemistry , receptor , chitosan , organic chemistry

For enhanced anti-cancer performance, human serum albumin fragments (HSAFs) nanoparticles (NPs) were developed as paclitaxel (PTX) carrier in this paper. Human albumins were broken into fragments via degradation and crosslinked by genipin to form HSAF NPs for better biocompatibility, improved PTX drug loading and sustained drug release. Compared with crosslinked human serum albumin NPs, the HSAF-NPs showed relative smaller particle size, higher drug loading, and improved sustained release. Cellular and animal results both indicated that the PTX encapsulated HSAF-NPs have shown good anti-cancer performance. And the anticancer results confirmed that NPs with fast cellular internalization showed better tumor inhibition. These findings will not only provide a safe and robust drug delivery NP platform for cancer therapy, but also offer fundamental information for the optimal design of albumin based NPs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research